<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632057</url>
  </required_header>
  <id_info>
    <org_study_id>CRD_914</org_study_id>
    <nct_id>NCT03632057</nct_id>
  </id_info>
  <brief_title>Shock Efficacy Study Comparing Fixed Tilt and Fixed Pulse Width in a General Implantable-Cardioverter Population</brief_title>
  <acronym>EFICAZ</acronym>
  <official_title>Shock Efficacy, a Randomized Study Comparing Fixed Tilt and Fixed Pulse Width in a General Implantable-Cardioverter Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, 1:1 randomized, interventional, multicenter and international trial.&#xD;
      Approximately 790 subjects are expected to be enrolled to 40 sites in the south of Europe and&#xD;
      Middle East.&#xD;
&#xD;
      The objective of this study is to evaluate and compare the efficacy of the first appropriate&#xD;
      shock of an ICD in a ventricular tachyarrhythmia, when the waveform of the shock is&#xD;
      programmed with the standard waveform, Fixed Tilt with a value of 65% (Control Group), versus&#xD;
      the exclusive waveform programmable in SJM ICDs, Fixed Pulse Width (Study Group), in a&#xD;
      standard population of subjects with ICD indication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the first appropriate shock to revert a tachyarrhythmia to sinus rhythm</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of rhythm conversion from Ventricular Tachyarrhythmia to sinus rhythm by the first appropriate shock programmed to 25 Joules (or equivalent voltage) programming the shock waveform in Fixed Pulse Width (Study Group) versus the Fixed Tilt with value 65% (Control Group).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">790</enrollment>
  <condition>Ventricular Arrythmia</condition>
  <arm_group>
    <arm_group_label>Fixed Tilt (65%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the control group, so device programming for shock energy is the default setting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Pulse Width</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the Study group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fixed Tilt (65%)</intervention_name>
    <description>This is the standard group, so device programming for shock energy is the default setting</description>
    <arm_group_label>Fixed Tilt (65%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fixed Pulse Width</intervention_name>
    <description>The device has to be programmed with fixed pulse width for each phase of the biphasic waveform</description>
    <arm_group_label>Fixed Pulse Width</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet the current ESC indications for ICD or CRT-D implant. This includes&#xD;
             upgrades indications from pacemaker to ICD or to CRT-D or replacements of ICDs or&#xD;
             CRT-Ds provided that there is no previous record of ineffective shocks&#xD;
&#xD;
               -  Subjects who are willing to be registered on the Merlin.net remote follow-up&#xD;
                  program&#xD;
&#xD;
               -  Subject ≥18 years&#xD;
&#xD;
               -  Subjects with life expectancy of at least 1 year&#xD;
&#xD;
               -  Subjects who agree to comply with the follow-up program included in this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Subjects on the waiting list for a heart transplant or under consideration for a&#xD;
             transplant over the next 12 months&#xD;
&#xD;
               -  Subjects with Myocardial infarction or unstable angina within 40 days prior to&#xD;
                  enrollment&#xD;
&#xD;
               -  Subjects who have undergone a recent cardiac revascularization (PTCA, Stent or&#xD;
                  CABG) procedure in the 4 weeks prior to enrollment&#xD;
&#xD;
               -  Functional NYHA Class IV&#xD;
&#xD;
               -  Subjects who are participating in another ICD or CRT-D study&#xD;
&#xD;
               -  Subjects who are pregnant at the time of enrollment or women of childbearing&#xD;
                  potential that do not take contraceptives&#xD;
&#xD;
               -  Any disability or limitations to correctly understand or complete the study&#xD;
                  (physical, intellectual, logistical)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Fernandez, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Javier Alzueta, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

